Comparative Pharmacology of Oral Fluoropyrimidines
Author Information
Author(s): Milano G, Ferrero J-M, François E
Primary Institution: Centre Antoine-Lacassagne
Hypothesis
The review aims to analyze the pharmacological properties of oral fluoropyrimidines, focusing on their metabolic activation and DPD inhibition.
Conclusion
Oral fluoropyrimidines differ significantly in their pharmacokinetic profiles and DPD inhibition, which can influence their clinical use.
Supporting Evidence
- 5-Fluorouracil is commonly prescribed for various cancers but has limitations due to administration methods.
- Oral prodrugs of 5-FU show different pharmacokinetic behaviors and DPD inhibition effects.
- DPD inhibitors can improve the pharmacokinetics of 5-FU, reducing variability in patient responses.
Takeaway
This study looks at different oral cancer drugs and how they work in the body, helping doctors choose the best treatment for patients.
Methodology
The review synthesizes existing literature on the pharmacokinetics and pharmacodynamics of various oral fluoropyrimidines.
Potential Biases
Potential biases in the studies reviewed may affect the conclusions drawn.
Limitations
The review is based on existing studies, which may have varying methodologies and sample sizes.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website